Equities Analysts Offer Predictions for Alector Q1 Earnings

Alector, Inc. (NASDAQ:ALEC - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Alector in a research note issued on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will earn ($0.54) per share for the quarter. The consensus estimate for Alector's current full-year earnings is ($1.88) per share. William Blair also issued estimates for Alector's Q2 2026 earnings at ($0.53) EPS, Q3 2026 earnings at ($0.54) EPS and Q4 2026 earnings at ($0.52) EPS.

Alector (NASDAQ:ALEC - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.59. The firm had revenue of $54.24 million for the quarter, compared to analysts' expectations of $20.41 million. Alector had a negative return on equity of 108.77% and a negative net margin of 257.54%.

A number of other research firms have also recently commented on ALEC. Bank of America cut shares of Alector from a "neutral" rating to an "underperform" rating and cut their price target for the company from $9.00 to $1.00 in a report on Wednesday, December 4th. BTIG Research lowered their price objective on Alector from $16.00 to $5.00 and set a "buy" rating on the stock in a research report on Tuesday, November 26th. Mizuho lowered Alector from an "outperform" rating to a "neutral" rating and reduced their target price for the stock from $9.00 to $2.50 in a report on Tuesday, December 17th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Alector in a report on Thursday, February 27th. Finally, Morgan Stanley downgraded Alector from an "equal weight" rating to an "underweight" rating and reduced their price objective for the stock from $10.00 to $3.00 in a report on Tuesday, November 26th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $3.75.

Alector Trading Up 3.2 %

NASDAQ:ALEC traded up $0.05 on Friday, reaching $1.46. 1,401,350 shares of the stock traded hands, compared to its average volume of 717,782. The company has a market capitalization of $144.17 million, a price-to-earnings ratio of -0.86 and a beta of 0.61. Alector has a 12 month low of $1.30 and a 12 month high of $7.10. The company's fifty day simple moving average is $1.76 and its 200 day simple moving average is $3.46.

Institutional Trading of Alector

Large investors have recently modified their holdings of the company. Creative Planning boosted its position in Alector by 54.2% in the third quarter. Creative Planning now owns 19,117 shares of the company's stock worth $89,000 after purchasing an additional 6,723 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Alector by 65.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 18,718 shares of the company's stock worth $87,000 after purchasing an additional 7,395 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Alector by 19.5% in the third quarter. Victory Capital Management Inc. now owns 186,747 shares of the company's stock worth $870,000 after buying an additional 30,513 shares during the last quarter. Intech Investment Management LLC bought a new stake in Alector during the third quarter valued at approximately $90,000. Finally, Massachusetts Financial Services Co. MA grew its position in Alector by 54.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 174,718 shares of the company's stock valued at $814,000 after buying an additional 61,798 shares during the period. Institutional investors own 85.83% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.